Kymera Therapeutics Announces First Patient Dosed In Phase 2 Hidradenitis Suppurativa Clinical Trial Of KT-474 (SAR444656); Under Terms Of Collaboration, Dosing Generates $40 Million Payment from Sanofi
Portfolio Pulse from Benzinga Newsdesk
Kymera Therapeutics has announced the first patient dosed in its Phase 2 Hidradenitis Suppurativa clinical trial of KT-474 (SAR444656). This event triggers a $40 million payment from Sanofi under the terms of their collaboration.
October 27, 2023 | 11:04 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Kymera Therapeutics has dosed the first patient in its Phase 2 trial of KT-474, triggering a $40 million payment from Sanofi.
The dosing of the first patient in the Phase 2 trial is a significant milestone for Kymera Therapeutics, as it not only advances the development of KT-474, but also triggers a substantial $40 million payment from Sanofi. This could provide a financial boost to the company and potentially positively impact its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100